eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2020-03-28 13 1 417 422 10.13005/bpj/1901 31133 article Anna Ariano Giorgio Attinà 1 Silvia Triarico 1 Paola Coccia 2 Michele Antonio Capozza 1 Antonio Ruggiero 1 Pediatric Oncology Unit, Fondazione Policlinico Universitario A .Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Roma, Italy. Pediatric Hemato-oncology Unit, Ospedale Salesi, Azienda Ospedali Riuniti Ancona, Ancona, Italy. Temozolomide, an alkylating drug first adopted to treat patients with malignant gliomas, is actually an antineoplastic drug used in various regimens against childhood tumors. Treatment with temozolomide is an effective therapy for different childhood tumor types: brain tumors, neuroblastomas, Ewing's sarcoma, and rhabdomyosarcomas. Temozolomide has been used both as monotherapy and in polychemotherapy in combination with epipodophyllotoxins, camptothecin analogues, platinum compounds, vinca alkaloids and radiotherapy. The present study analyzes the treatment schedules including temozolomide in different cancer pathologies by comparing the results, in order to evaluate the efficacy of each treatment modality. https://biomedpharmajournal.org/vol13no1/efficacy-of-temozolomide-in-children-with-solid-tumors/ Children Solid Tumors Temozolomide